This product is for research use only, not for human use. We do not sell to patients.
| Size | Price | Stock |
|---|---|---|
| 100mg | $550 | Check With Us |
| 250mg | $1050 | Check With Us |
| 1g | $1575 | Check With Us |
: Cat #: V2254 CAS #: 1473450-62-2 Purity ≥ 99%
Description: NITD-349 is a novel and potent MmpL3 inhibitor, it shows highly potent anti-mycobacterial activity (MIC50=23 nM) against virulent Mycobacterium tuberculosis H37Rv.
References: [1]. Rao SP, et al. Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. Sci Transl Med. 2013 Dec 4;5(214):214ra168.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 306.35 |
|---|---|
| Molecular Formula | C₁₇H₂₀F₂N₂ |
| CAS No. | 1473450-62-2 |
| SMILES Code | O=C(C(N1)=CC2=C1C=C(F)C=C2F)NC3CCC(C)(C)CC3 |
| Synonyms | NITD-349; NITD 349; NITD349; |
| Protocol | In Vitro | NITD-349 shows bactericidal activity against in vitro replicating Mycobacterium tuberculosis (Mtb) and also are active against intramacrophage Mtb. Kill kinetic analysis of these compounds showed both concentration- and time-dependent killing of Mtb cells with 3- to 4-log colony-forming unit (CFU) reductionwithin 3 days of treatment. The cidal activity profile of NITD-304 is similar to that of isoniazid for which rapid killing is noticed at concentrations greater than 0.2 μM. The MIC activity of NITD349 against various MDR Mtb strains ranges from 0.04 to 0.08 μM. NITD-349 shows high permeability and moderate in vitro metabolic clearance in mouse and human hepatic microsomes. |
|---|---|---|
| In Vivo | In the acute murine efficacy modelNITD-349 shows favorable oral pharmacokinetic (PK) properties in rodents and dogs and are efficacious in mouse models of both acute and chronic Mycobacterium tuberculosis infection. In the acute murine efficacy model, treatment of mice with NITD-349 at doses of 12.5 and 50 mg/kg resulted in 0.9- and 3.4-log CFU reduction in lung tissue. In an established infection mouse model, after 2 weeks of treatment, the efficacy of NITD-349 is comparable to the first-line TB drug rifampicin and is better than ethambutol. Four weeks of treatment at 100 mg/kg with NITD-349 results in 2.38-log CFU reductions. |
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 3.2642 mL | 16.3212 mL | 32.6424 mL | 65.2848 mL |
| 5mM | 0.6528 mL | 3.2642 mL | 6.5285 mL | 13.0570 mL |
| 10mM | 0.3264 mL | 1.6321 mL | 3.2642 mL | 6.5285 mL |
| 20mM | 0.1632 mL | 0.8161 mL | 1.6321 mL | 3.2642 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.